Corey A Siegel1. 1. Inflammatory Bowel Disease Center, Section of Gastroenterology and Hepatology, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire 03755, USA. corey.a.siegel@hitchcock.org
Abstract
PURPOSE OF REVIEW: The treatment of inflammatory bowel disease (IBD) is becoming more complex due to the introduction of new medications and evolving treatment algorithms. Data suggest that more aggressive treatment will yield improved clinical results. Although promising, it is not clear if patients will agree to this new approach. This review aims to describe what we know about patients' perceptions of risks and benefits of treatment, how much risk IBD patients are willing to accept, and to introduce ideas to facilitate better patient communication. RECENT FINDINGS: Patients and parents of children with IBD appear to be willing to accept the known risks associated with IBD therapies, but demand substantial treatment benefit to make this tradeoff. As patients with IBD have misperceptions about the risks and benefits of treatment, it is important to develop better methods of communicating medical information. SUMMARY: There are now more treatment options for patients with IBD. To increase patients' participation in medical decisions, it is critical to fairly present the tradeoffs of risks versus benefits of treatment. Tools are being developed to more clearly present clinical trial data, risks of medication side effects and for calculating individualized risks of disease complications and response to therapy.
PURPOSE OF REVIEW: The treatment of inflammatory bowel disease (IBD) is becoming more complex due to the introduction of new medications and evolving treatment algorithms. Data suggest that more aggressive treatment will yield improved clinical results. Although promising, it is not clear if patients will agree to this new approach. This review aims to describe what we know about patients' perceptions of risks and benefits of treatment, how much risk IBD patients are willing to accept, and to introduce ideas to facilitate better patient communication. RECENT FINDINGS:Patients and parents of children with IBD appear to be willing to accept the known risks associated with IBD therapies, but demand substantial treatment benefit to make this tradeoff. As patients with IBD have misperceptions about the risks and benefits of treatment, it is important to develop better methods of communicating medical information. SUMMARY: There are now more treatment options for patients with IBD. To increase patients' participation in medical decisions, it is critical to fairly present the tradeoffs of risks versus benefits of treatment. Tools are being developed to more clearly present clinical trial data, risks of medication side effects and for calculating individualized risks of disease complications and response to therapy.
Authors: Gert Van Assche; Marc Van Ranst; Raf Sciot; Bénédicte Dubois; Séverine Vermeire; Maja Noman; Jannick Verbeeck; Karel Geboes; Wim Robberecht; Paul Rutgeerts Journal: N Engl J Med Date: 2005-06-09 Impact factor: 91.245
Authors: Stephen B Hanauer; Brian G Feagan; Gary R Lichtenstein; Lloyd F Mayer; S Schreiber; Jean Frederic Colombel; Daniel Rachmilewitz; Douglas C Wolf; Allan Olson; Weihang Bao; Paul Rutgeerts Journal: Lancet Date: 2002-05-04 Impact factor: 79.321
Authors: Annette M O'Connor; John E Wennberg; France Legare; Hilary A Llewellyn-Thomas; Benjamin W Moulton; Karen R Sepucha; Andrea G Sodano; Jaime S King Journal: Health Aff (Millwood) Date: 2007 May-Jun Impact factor: 6.301
Authors: Jaya Punati; James Markowitz; Trudy Lerer; Jeffrey Hyams; Subra Kugathasan; Anne Griffiths; Anthony Otley; Joel Rosh; Marian Pfefferkorn; David Mack; Jonathan Evans; Athos Bousvaros; M Susan Moyer; Robert Wyllie; Maria Oliva-Hemker; Adam Mezoff; Neal Leleiko; David Keljo; Wallace Crandall Journal: Inflamm Bowel Dis Date: 2008-07 Impact factor: 5.325
Authors: Jennifer L Bennett; Christina Y Ha; Jonathan E Efron; Susan L Gearhart; Mark G Lazarev; Elizabeth C Wick Journal: World J Gastroenterol Date: 2015-01-28 Impact factor: 5.742